Unknown OBSERVATIONAL NCT05647785

Long-term Follow-up of RESTORE Study

Extension Study to Compare Long-term Efficacy of Two Digital Software Medical Devices as Interventions for Physical and Mental Health in Cancer Patients Previously Enrolled in the RESTORE Study

Sponsor: Blue Note Therapeutics

Conditions Cancer

Interventions Long-term follow-up of attune™ Long-term follow-up of cerena™

Updated 4 times since 2023 Last updated: Dec 9, 2022 Started: Oct 31, 2022 Primary completion: May 31, 2023 Completion: Jun 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Cancer and is currently ongoing. Blue Note Therapeutics leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Jan 2025 — Present [monthly]

Unknown

Status: Enrolling By Invitation → Unknown
Sep 2024 — Jan 2025 [monthly]

Enrolling By Invitation
Jul 2024 — Sep 2024 [monthly]

Enrolling By Invitation
Jan 2023 — Jul 2024 [monthly]

Enrolling By Invitation

First recorded

Oct 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Blue Note Therapeutics

Data source: Blue Note Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Francisco, United States